S&P 500   3,791.15 (+1.08%)
DOW   30,659.29 (+1.18%)
QQQ   320.34 (+0.28%)
AAPL   138.84 (-2.27%)
MSFT   235.79 (+1.24%)
FB   284.54 (+4.56%)
GOOGL   1,845.86 (+1.48%)
AMZN   3,238.13 (+0.17%)
TSLA   818.29 (-5.31%)
NVDA   520.55 (+0.74%)
BABA   259.36 (-0.34%)
CGC   38.14 (+0.82%)
GE   11.36 (-0.18%)
MU   77.17 (+2.77%)
AMD   88.52 (-0.36%)
NIO   56.18 (-1.70%)
T   29.01 (-0.45%)
F   10.81 (+0.19%)
ACB   11.64 (+3.93%)
BA   198.46 (+2.28%)
DIS   167.19 (+2.55%)
NFLX   532.95 (+1.85%)
GILD   65.33 (-0.23%)
S&P 500   3,791.15 (+1.08%)
DOW   30,659.29 (+1.18%)
QQQ   320.34 (+0.28%)
AAPL   138.84 (-2.27%)
MSFT   235.79 (+1.24%)
FB   284.54 (+4.56%)
GOOGL   1,845.86 (+1.48%)
AMZN   3,238.13 (+0.17%)
TSLA   818.29 (-5.31%)
NVDA   520.55 (+0.74%)
BABA   259.36 (-0.34%)
CGC   38.14 (+0.82%)
GE   11.36 (-0.18%)
MU   77.17 (+2.77%)
AMD   88.52 (-0.36%)
NIO   56.18 (-1.70%)
T   29.01 (-0.45%)
F   10.81 (+0.19%)
ACB   11.64 (+3.93%)
BA   198.46 (+2.28%)
DIS   167.19 (+2.55%)
NFLX   532.95 (+1.85%)
GILD   65.33 (-0.23%)
S&P 500   3,791.15 (+1.08%)
DOW   30,659.29 (+1.18%)
QQQ   320.34 (+0.28%)
AAPL   138.84 (-2.27%)
MSFT   235.79 (+1.24%)
FB   284.54 (+4.56%)
GOOGL   1,845.86 (+1.48%)
AMZN   3,238.13 (+0.17%)
TSLA   818.29 (-5.31%)
NVDA   520.55 (+0.74%)
BABA   259.36 (-0.34%)
CGC   38.14 (+0.82%)
GE   11.36 (-0.18%)
MU   77.17 (+2.77%)
AMD   88.52 (-0.36%)
NIO   56.18 (-1.70%)
T   29.01 (-0.45%)
F   10.81 (+0.19%)
ACB   11.64 (+3.93%)
BA   198.46 (+2.28%)
DIS   167.19 (+2.55%)
NFLX   532.95 (+1.85%)
GILD   65.33 (-0.23%)
S&P 500   3,791.15 (+1.08%)
DOW   30,659.29 (+1.18%)
QQQ   320.34 (+0.28%)
AAPL   138.84 (-2.27%)
MSFT   235.79 (+1.24%)
FB   284.54 (+4.56%)
GOOGL   1,845.86 (+1.48%)
AMZN   3,238.13 (+0.17%)
TSLA   818.29 (-5.31%)
NVDA   520.55 (+0.74%)
BABA   259.36 (-0.34%)
CGC   38.14 (+0.82%)
GE   11.36 (-0.18%)
MU   77.17 (+2.77%)
AMD   88.52 (-0.36%)
NIO   56.18 (-1.70%)
T   29.01 (-0.45%)
F   10.81 (+0.19%)
ACB   11.64 (+3.93%)
BA   198.46 (+2.28%)
DIS   167.19 (+2.55%)
NFLX   532.95 (+1.85%)
GILD   65.33 (-0.23%)
Log in
NASDAQ:APDN

Applied DNA Sciences Stock Forecast, Price & News

$10.40
-0.47 (-4.32 %)
(As of 01/28/2021 09:34 AM ET)
Add
Compare
Today's Range
$10.25
Now: $10.40
$10.52
50-Day Range
$5.10
MA: $7.53
$11.64
52-Week Range
$2.52
Now: $10.40
$16.39
Volume912 shs
Average Volume3.40 million shs
Market Capitalization$77.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications and can be used to fortify brand protection efforts, and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide definitive real-time authentication of molecular tags in the field; and CertainT Supply Chain Platform that provides proof of product claims for materials, items, or products. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Applied DNA Sciences logo

MarketRank

Overall MarketRank

1.24 out of 5 stars

Industrial Products Sector

165th out of 398 stocks

Miscellaneous Business Services Industry

6th out of 18 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Miscellaneous business services
Sub-IndustryN/A
Current SymbolNASDAQ:APDN
CUSIPN/A
Phone631-840-8800
Employees59
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.93 million
Book Value$1.11 per share

Profitability

Net Income$-13,030,000.00
Net Margins-672.79%

Miscellaneous

Market Cap$77.70 million
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$10.40
-0.47 (-4.32 %)
(As of 01/28/2021 09:34 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APDN News and Ratings via Email

Sign-up to receive the latest news and ratings for APDN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Applied DNA Sciences (NASDAQ:APDN) Frequently Asked Questions

How has Applied DNA Sciences' stock price been impacted by COVID-19?

Applied DNA Sciences' stock was trading at $4.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APDN stock has increased by 165.1% and is now trading at $10.87.
View which stocks have been most impacted by COVID-19
.

Is Applied DNA Sciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied DNA Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Applied DNA Sciences stock.
View analyst ratings for Applied DNA Sciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Applied DNA Sciences?

Wall Street analysts have given Applied DNA Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Applied DNA Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is James A. Hayward's approval rating as Applied DNA Sciences' CEO?

2 employees have rated Applied DNA Sciences CEO James A. Hayward on Glassdoor.com. James A. Hayward has an approval rating of 100% among Applied DNA Sciences' employees. This puts James A. Hayward in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Applied DNA Sciences' next earnings date?

Applied DNA Sciences is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Applied DNA Sciences
.

How were Applied DNA Sciences' earnings last quarter?

Applied DNA Sciences, Inc. (NASDAQ:APDN) released its quarterly earnings results on Wednesday, December, 16th. The technology company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.26. The technology company earned $0.31 million during the quarter, compared to analyst estimates of $0.70 million. Applied DNA Sciences had a negative trailing twelve-month return on equity of 179.48% and a negative net margin of 672.79%.
View Applied DNA Sciences' earnings history
.

What guidance has Applied DNA Sciences issued on next quarter's earnings?

Applied DNA Sciences issued an update on its first quarter 2021 Pre-Market earnings guidance on Monday, January, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.3-1.6 million, compared to the consensus revenue estimate of $1.05 million.

What price target have analysts set for APDN?

2 Wall Street analysts have issued 12 month price targets for Applied DNA Sciences' shares. Their forecasts range from $14.00 to $21.00. On average, they anticipate Applied DNA Sciences' stock price to reach $17.50 in the next year. This suggests a possible upside of 61.0% from the stock's current price.
View analysts' price targets for Applied DNA Sciences
or view Wall Street analyst' top-rated stocks.

Are investors shorting Applied DNA Sciences?

Applied DNA Sciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 662,200 shares, an increase of 47.3% from the December 15th total of 449,600 shares. Based on an average daily volume of 260,400 shares, the short-interest ratio is currently 2.5 days. Approximately 13.8% of the company's shares are short sold.
View Applied DNA Sciences' Short Interest
.

Who are some of Applied DNA Sciences' key competitors?

What other stocks do shareholders of Applied DNA Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied DNA Sciences investors own include Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Ekso Bionics (EKSO), Micron Technology (MU), Arbutus Biopharma (ABUS), VBI Vaccines (VBIV), Gilead Sciences (GILD), Vaxart (VXRT), Sorrento Therapeutics (SRNE) and Intel (INTC).

Who are Applied DNA Sciences' key executives?

Applied DNA Sciences' management team includes the following people:
  • Dr. James A. Hayward Ph.D., Sc.D., Chairman, Pres & CEO (Age 67, Pay $249.31k)
  • Ms. Beth M. Jantzen CPA, CPA, Chief Financial Officer (Age 45, Pay $221.54k)
  • Ms. Judith Murrah, Chief Information Officer & Sec. (Age 63, Pay $221.54k)
  • Mr. Sanjay M. Hurry, Exec. Director of Investor Relations & Corp. Communications
  • Mr. Clay Shorrock Esq., Gen. Counsel
  • Mr. John Shearman, Exec. Director of Marketing & Cannabis Bus.
  • Mr. Tony Benson, Managing Director of EMEA
  • Mr. Scott L. Anchin, Strategic Advisor & Director (Age 47)
  • Ms. Janice Meraglia, VP, Gov. & Military Programs
  • Ms. MeiLin Wan, VP of Textile Sales

What is Applied DNA Sciences' stock symbol?

Applied DNA Sciences trades on the NASDAQ under the ticker symbol "APDN."

Who are Applied DNA Sciences' major shareholders?

Applied DNA Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Golden Green Inc. (0.24%).
View institutional ownership trends for Applied DNA Sciences
.

Which institutional investors are buying Applied DNA Sciences stock?

APDN stock was acquired by a variety of institutional investors in the last quarter, including Golden Green Inc..
View insider buying and selling activity for Applied DNA Sciences
or or view top insider-buying stocks.

How do I buy shares of Applied DNA Sciences?

Shares of APDN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Applied DNA Sciences' stock price today?

One share of APDN stock can currently be purchased for approximately $10.87.

How big of a company is Applied DNA Sciences?

Applied DNA Sciences has a market capitalization of $81.21 million and generates $1.93 million in revenue each year. The technology company earns $-13,030,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis. Applied DNA Sciences employs 59 workers across the globe.

What is Applied DNA Sciences' official website?

The official website for Applied DNA Sciences is www.adnas.com.

How can I contact Applied DNA Sciences?

Applied DNA Sciences' mailing address is 50 HEALTH SCIENCES DRIVE, STONY BROOK NY, 11790. The technology company can be reached via phone at 631-840-8800 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.